Authored By: Sarah
15 Jul 2024

 Tyrosine Kinase Inhibitors Market Size to grow by USD 24.22 billion between 2024-2028

According to a research report “ Tyrosine Kinase Inhibitors Market” by Distribution Channel (Offline, Online) Product (RTKIs, nRTKIs) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 24.22 billion, at a CAGR of 8.42% during the forecast period. In the realm of oncology, the advanced or recurring cancer treatment landscape remains unsatisfactory due to challenges in drug pharmacokinetics and pharmacodynamics. Current therapies, such as chemotherapy and the standard of care (SoC) treatments, often come with debilitating side effects, including bone marrow suppression, diarrhea, and alopecia, which negatively impact patient adherence. Tyrosine kinase inhibitors (TKIs), a class of promising oncology drugs, have emerged as a potential solution to address these limitations. Extensive research in the field of oncology has revealed that TKIs can effectively target cancer cells, offering a more tolerable treatment option for patients..

Browse market data tables, figures, and in-depth TOC on “Tyrosine Kinase Inhibitors Market” by Distribution Channel (Offline, Online) Product (RTKIs, nRTKIs) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Distribution Channel, the Offline segment is projected to dominate the market size in 2024

In the dynamic and innovative pharmaceutical landscape, receptor tyrosine kinase inhibitors (RTKIs) represent a significant class of drugs that target specific receptors, namely tyrosine kinases, on the cell surface. These enzymes are integral to cell signaling pathways regulating cell growth, differentiation, and survival. By selectively inhibiting these receptors, RTKIs disrupt the signaling cascade, particularly in cancer treatment where dysregulation of these pathways contributes to uncontrolled cell growth. RTKIs have emerged as a critical component of targeted therapy, offering precision in addressing cancers driven by specific genetic mutations or overactive signaling pathways. Success stories include imatinib, which targets BCR-ABL in chronic myeloid leukemia, and EGFR inhibitors like erlotinib and gefitinib in non-small cell lung cancer. In the global tyrosine kinase inhibitors market, these drugs hold immense potential, reflecting a substantial market share and growth prospects.

By Product, RTKIs  segment is expected to hold the largest market size for the year 2024

In the pharmaceutical industry, intermediaries play a crucial role in the distribution of tyrosine kinase inhibitors (TKIs). The offline segment, consisting of wholesalers, distributors, and retailers, is responsible for supplying these essential drugs to healthcare facilities and pharmacies. Wholesalers serve as the primary link between TKI manufacturers and local distributors, maintaining vast inventories in their warehouses before shipping the drugs. These intermediaries collaborate with multiple TKI manufacturers, ensuring a diverse range of products is accessible to healthcare providers and ultimately, patients.

North America is forecasted to hold the largest market size by region in 2024

The North American tyrosine kinase inhibitors market is experiencing significant growth due to the substantial prevalence of cancer and the resulting high unmet need for effective treatments. According to the National Cancer Institute, cancer has a profound impact on society in the US and globally, with over 28.5 million invasive cancer cases diagnosed in the last two decades. With over one million new cases reported annually, the demand for advanced therapeutic solutions, such as tyrosine kinase inhibitors, is escalating. These inhibitors play a crucial role in addressing the complexities of cancer and offer promising treatment options for patients.

The Tyrosine Kinase Inhibitors Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Danaher Corp.
  • Deciphera Pharmaceuticals Inc.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • Exelixis Inc.
  • F. Hoffmann La Roche Ltd.
  • Johnson and Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology Inc.
  • Rigel Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Tokyo Chemical Industry Co. Ltd.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Tyrosine Kinase Inhibitors (TKIs) market is witnessing significant growth due to the increasing prevalence of diabetes and cancer. TKIs are a class of drugs that inhibit the activity of specific tyrosine kinases, which play crucial roles in cell signaling pathways involved in cell cycle, cell proliferation, cell differentiation, and cell apoptosis. These signaling pathways are often dysregulated in various diseases, including diabetes and cancer. In cancer, TKIs have shown promising results in inhibiting the activity of kinases involved in signal transduction cascades, such as BRAF Kinase and ROS1. Imatinib, a well-known TKI, has revolutionized the treatment of chronic myelogenous leukemia and certain types of gastrointestinal stromal tumors. Research activities in TKIs are ongoing, with a focus on developing new drugs for various types of cancer, including breast, renal cell, and lung cancer. Molecular modeling and clinical trials are being used to understand the mechanism of action and optimize the efficacy and safety of these drugs. The growing burden of cancer and the need for effective treatments in healthcare systems are expected to drive the growth of the TKIs market in the coming years.

Market Research Overview

The Tyrosine Kinase Inhibitors (TKIs) market is experiencing significant growth due to the increasing prevalence of cancer cases and the development of novel therapies. Both inorganic and organic growth strategies are being employed by key players such as Boehringer Ingelheim, Insilico Medicine, and others to expand their presence in this market. PEST analysis reveals that supply side factors like increasing research activities and drug discovery are driving the market, while demand side factors like the rising number of cancer cases and the need for effective treatment drugs are fueling the growth. The TKIs market trend analysis indicates the development of new drugs like Asciminib, Osimertinib, GioTag, and others, which target various therapeutic targets such as EGFR TKIs for gastrointestinal tumors and BCR-ABL TKIs for leukemia. The high development cost of these drugs and the public health crisis caused by cancer are major challenges for the market. However, the use of profiling techniques, assays, and molecular modeling in drug discovery is helping to overcome these challenges. Future trends in the TKIs market include the development of DDR1 kinase inhibitors for fibrosis, ROS1 Inhibitors for lung cancer, and BRAF Kinase Inhibitors for breast cancer. The biotechnology industry is also exploring the use of vaccines and artificial intelligence in the development of TKIs. Inflammation, diabetes, cell apoptosis, cell cycle, cell differentiation, and cell proliferation are some of the key areas of research in the TKIs market. The phosphate group plays a crucial role in signal transduction cascades, making it a significant focus for TKIs. Cancer Research UK reports that cancer cases are on the rise, with breast, renal cell, and lung cancer being the most common types. The healthcare systems of various countries are under pressure to provide effective and affordable treatment options for cancer patients. The market price of TKIs is a major concern, and efforts are being made to make these drugs more accessible to patients. In conclusion, the Tyrosine Kinase Inhibitors market is poised for significant growth due to the increasing prevalence of cancer cases and the development of novel therapies. The challenges of high development cost and public health crisis are being addressed through the use of advanced technologies and research activities. The future trends in the market include the development of new drugs for various types of cancer and the use of artificial intelligence and vaccines in drug discovery.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio